Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
18.43
-0.26 (-1.39%)
May 28, 2026, 1:44 PM EDT - Market open
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or -4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
$254,081
Profits / Employee
-$99,840
Market Cap
2.07B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Stoke Therapeutics | 170 |
| Kodiak Sciences | 130 |
| Pharvaris | 129 |
| Aurinia Pharmaceuticals | 128 |
| Nanobiotix | 100 |
| Tyra Biosciences | 87 |
| Rapport Therapeutics | 84 |
| Mesoblast | 81 |
ZLAB News
- 6 days ago - Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments - GuruFocus
- 6 days ago - Zai Lab announces departure of COO Josh Smiley - TheFly
- 6 days ago - Zai Lab Announces Changes to Senior Leadership Team - Business Wire
- 12 days ago - Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 17 days ago - Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment - GuruFocus
- 17 days ago - Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan - TheFly
- 17 days ago - Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - Business Wire
- 19 days ago - Zai Lab Q1 Earnings Call Highlights - MarketBeat